Trial Profile
Phase II Trial of Sunitinib (SU11248) in Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers and Medullary Thyroid Cancers
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 28 Jul 2022
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Adenocarcinoma; Thyroid cancer
- Focus Therapeutic Use
- 17 Jun 2016 Planned primary completion date changed from 1 May 2016 to 1 Dec 2016.
- 08 Dec 2015 Planned primary completion date changed from 1 Dec 2015 to 1 May 2016, according to ClinicalTrials.gov record.
- 14 Apr 2015 Planned primary completion date changed from 1 Apr 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov record.